This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paltiel, A. D. Articles by Freedberg, K. A. Search for Related Content

The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients

Yale School of Medicine, 60 College Street, New Haven, Connecticut 06520-8034
Clinical Economics Research Unit, Section of General Internal Medicine, Department of Medicine and Thorndike Memorial Laboratory, Boston Medical Center, Boston University School of Medicine, 91 East Concord Street, Suite 200, Boston, Massachusetts 02118

To examine the costs and consequences of prophylaxis against cytomegalovirus (CMV) infection, we developed a compartmental model of the natural history of late-stage HIV disease. We used data on the progression of illness, economic costs, the incidence of infections, the efficacy and toxicity of therapy, and patient quality of life from national cohort studies, randomized clinical trials, and resource-utilization surveys. We found that CMV prophylaxis confers additional quality-adjusted life-years at a lower-bound, marginal cost of $160,000. While this cost-effectiveness result compares unfavorably with alternative uses of scarce resources, it is sensitive to assumptions regarding the price of therapy and the incidence of infection.

Key Words: health care; cost analysis

This article has been cited by other articles:

				J. G. Kahn, M. L. Brandeau, and J. Dunn-Mortimer OR Modeling and AIDS Policy: From Theory to Practice Interfaces, May 1, 1998; 28(3): 3 - 22. [Abstract] [PDF]